Assignee
UNION THERAPEUTICS AS
DK·21 granted patents·13 pending applications·95 citations·filing 2016–2025
Top patents by PatentIndex Score
34 records- 0196US10463680B2Halogenated salicylanilides for treating clostridium infectionsUNION THERAPEUTICS AS·Filed 2016·Granted Nov 5, 2019·19 cites·21 claims
- 0294US11045434B1Niclosamide formulations for treating diseaseUNION THERAPEUTICS AS·Filed 2020·Granted Jun 29, 2021·24 cites·23 claims
- 0392US11324708B1Niclosamide formulations for treating diseaseUNION THERAPEUTICS AS·Filed 2021·Granted May 10, 2022·3 cites·6 claims
- 0492US10758553B2Antibacterial use of halogenated salicylanilidesUNION THERAPEUTICS AS·Filed 2018·Granted Sep 1, 2020·10 cites·21 claims
- 0591US11285164B2Antibacterial use of halogenated salicylanilidesUNION THERAPEUTICS AS·Filed 2020·Granted Mar 29, 2022·2 cites·8 claims
- 0690US11981681B2Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitorsUNION THERAPEUTICS AS·Filed 2022·Granted May 14, 2024·1 cites·21 claims
- 0790US11365204B2Substituted dihydrothienopyrimidines and their use as phosphodiesterase inhibitorsUNION THERAPEUTICS AS·Filed 2018·Granted Jun 21, 2022·5 cites·17 claims
- 0889US11866445B2Substituted dihydrothienopyrimidines and their use as phosphodiesterase inhibitorsUNION THERAPEUTICS AS·Filed 2022·Granted Jan 9, 2024·1 cites·28 claims
- 0989US11292799B2Substituted azetidine dihydrothienopyrimidines and their use as phosphodiesterase inhibitorsUNION THERAPEUTICS AS·Filed 2018·Granted Apr 5, 2022·5 cites·12 claims
- 1088US10857164B2Halogenated salicylanilides for treating Clostridium infectionsUNION THERAPEUTICS AS·Filed 2019·Granted Dec 8, 2020·10 cites·21 claims
- 1186US11529361B2Halogenated salicylanilides for treating Clostridium infectionsUNION THERAPEUTICS AS·Filed 2020·Granted Dec 20, 2022·1 cites·22 claims
- 1284US11384096B2Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitorsUNION THERAPEUTICS AS·Filed 2018·Granted Jul 12, 2022·4 cites·12 claims
- 1381US11299497B2Substituted tetrahydropyran dihydrothienopyrimidines and their use as phosphodiesterase inhibitorsUNION THERAPEUTICS AS·Filed 2018·Granted Apr 12, 2022·2 cites·12 claims
- 1480US11370799B2Methods for the preparation of 1,3-benzodioxole heterocyclic compoundsUNION THERAPEUTICS AS·Filed 2016·Granted Jun 28, 2022·4 cites·16 claims
- 1580US11220514B2Methods for the preparation of 1,3-benzodioxole heterocyclic compoundsUNION THERAPEUTICS AS·Filed 2018·Granted Jan 11, 2022·4 cites·13 claims
- 1678US2024400578A1Substituted azetidine dihydrothienopyridines and their use as phosphodiesterase inhibitorsUNION THERAPEUTICS AS·Filed 2024·Application pending·0 cites
- 1777US2026035383A1Methods for the preparation of 1,3-benzodioxole heterocyclic compoundsUNION THERAPEUTICS AS·Filed 2025·Application pending·0 cites
- 1873US11331327B2Antibacterial use of halogenated salicylanilidesUNION THERAPEUTICS AS·Filed 2020·Granted May 17, 2022·0 cites·6 claims
- 1973US11324761B2Antibacterial use of halogenated salicylanilidesUNION THERAPEUTICS AS·Filed 2020·Granted May 10, 2022·0 cites·5 claims
- 2068US2022323384A1Niclosamide formulations for treating diseaseUNION THERAPEUTICS AS·Filed 2022·Application pending·0 cites
- 2164US2023073362A1Methods for the preparation of 1,3-benzodioxole heterocyclic compoundsUNION THERAPEUTICS AS·Filed 2022·Application pending·0 cites
- 2260US12084457B2Methods for the preparation of 1,3-benzodioxole heterocyclic compoundsUNION THERAPEUTICS AS·Filed 2021·Granted Sep 10, 2024·0 cites·21 claims
- 2357US12409172B2Dosage regimenUNION THERAPEUTICS AS·Filed 2024·Granted Sep 9, 2025·0 cites·23 claims
- 2455US2022265683A1Halogenated salicylanilides for the treatment of dermatitisUNION THERAPEUTICS AS·Filed 2019·Application pending·0 cites
- 2553US2021137948A1Treatment of infections caused by neisseria gonococcus using a halogenated salicylanilideUNION THERAPEUTICS AS·Filed 2019·Application pending·0 cites
- 2652US2023147683A1TreatmentUNION THERAPEUTICS AS·Filed 2021·Application pending·0 cites
- 2752US2023190685A1FormulationUNION THERAPEUTICS AS·Filed 2021·Application pending·0 cites
- 2851US2025268876A1Treatment of hidradenitis suppurativa with orismilastUNION THERAPEUTICS AS·Filed 2022·Application pending·0 cites
- 2950US2021386674A1Modified release tablet formulations containing phosphodiesterase inhibitorUNION THERAPEUTICS AS·Filed 2020·Application pending·0 cites
- 3050US2021379085A1Halogenated salicylanilides for treating the symptoms of dermatitisUNION THERAPEUTICS AS·Filed 2019·Application pending·0 cites
- 3149US11213533B2Combinations comprising dibromopropamidine or diminazene and a tetracycline anti-bacterial agentUNION THERAPEUTICS AS·Filed 2017·Granted Jan 4, 2022·0 cites·15 claims
- 3246US2021369650A1Treatment of inflammatory conditionsUNION THERAPEUTICS AS·Filed 2018·Application pending·0 cites
- 3344US2026069578A1Treatment of neutrophilic dermatosesUNION THERAPEUTICS AS·Filed 2023·Application pending·0 cites
- 3440US12036312B2Non-aqueous topical compositions comprising a halogenated salicylanilideUNION THERAPEUTICS AS·Filed 2017·Granted Jul 16, 2024·0 cites·30 claims
Join the waitlist — get patent alerts
Get an alert when UNION THERAPEUTICS AS files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →